8-K/AOther Events

JOHNSON & JOHNSON 8-K/A Report (Nov 30, 2001)

Filed November 30, 2001For Securities:JNJ

Summary

Johnson & Johnson (JNJ) filed an amendment to its Current Report on Form 8-K on November 29, 2001, reporting on an event that occurred on November 21, 2001. The primary purpose of this amendment was to officially announce the completion of J&J's acquisition of the diabetes care products business from Inverness Medical Technology, Inc. This strategic move signals J&J's continued investment and expansion within the rapidly growing diabetes care market, aiming to enhance its product portfolio and market presence in this critical healthcare segment. Investors should note that this acquisition aligns with J&J's broader strategy of strengthening its consumer health and medical device segments through targeted acquisitions. The integration of Inverness's diabetes care assets is expected to contribute to future revenue growth and provide synergistic opportunities within J&J's existing healthcare offerings. Further details on the financial impact and operational integration are anticipated in subsequent filings.

Key Highlights

  • 1Johnson & Johnson (JNJ) announced the completion of its acquisition of Inverness Medical Technology, Inc.'s diabetes care products business.
  • 2The acquisition was officially reported via an amended Form 8-K filed on November 29, 2001, with the earliest event date noted as November 21, 2001.
  • 3This strategic acquisition focuses on expanding J&J's presence in the diabetes care market.
  • 4The move suggests J&J's commitment to growth in key healthcare segments through acquisitions.
  • 5The press release announcing the transaction is included as an exhibit to the filing.
  • 6The filing was signed by Stephen J. Cosgrove, Corporate Controller, indicating internal authorization.

Frequently Asked Questions

The main event reported was the completion of Johnson & Johnson's acquisition of the diabetes care products business from Inverness Medical Technology, Inc.

The earliest event date reported for this acquisition was November 21, 2001, and the acquisition completion was announced via a press release on that date.

This filing is an amendment (8-K/A) because it amends and restates a previously filed Form 8-K dated November 27, 2001, to officially announce the completion of the Inverness Medical Technology diabetes care business acquisition.

The acquisition is strategically important as it strengthens Johnson & Johnson's position in the growing diabetes care market, expanding its product offerings and market reach in a critical healthcare segment.